Related Experiment Videos

The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension

Cristina Sierra1, Antonio Coca

  • 1Department of Internal Medicine, Institute of Medicine and Dematology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain. csierra@clinic.ub.es

Expert Review of Cardiovascular Therapy
|September 17, 2008
PubMed

Insights

The ACTION trial investigated nifedipine gastrointestinal therapeutic system for coronary heart disease. Results from this study provide updated insights into calcium antagonist safety and efficacy in cardiovascular patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease and cerebrovascular disease are leading causes of death globally.
  • Hypertension is a primary cardiovascular risk factor, often co-occurring with coronary disease.
  • Calcium antagonists are used for hypertension and angina, but their cardiovascular safety was debated in the 1990s.

Purpose of the Study:

  • To investigate the effects of nifedipine gastrointestinal therapeutic system on clinical outcomes in patients with stable, symptomatic coronary disease.
  • To provide an update on the reported ACTION study results from various studies and subgroups.
  • To address the safety concerns surrounding calcium antagonists in cardiovascular disease treatment.

Main Methods:

  • The study involved patients with stable, symptomatic coronary disease, with a significant portion also being hypertensive.
  • Utilized the nifedipine gastrointestinal therapeutic system, a long-acting calcium antagonist.
  • Analysis of reported results from different studies and subgroups of the ACTION trial.

Main Results:

  • The ACTION study evaluated clinical outcomes in patients with coronary disease.
  • Subgroup analyses and updated reports provide further insights into the drug's effects.
  • The study aimed to clarify the role of calcium antagonists in managing cardiovascular conditions.

Conclusions:

  • The ACTION trial provides crucial data on the use of nifedipine gastrointestinal therapeutic system in coronary heart disease.
  • Updated results contribute to understanding calcium antagonist efficacy and safety in cardiovascular patients.
  • Further subgroup analyses may refine clinical practice guidelines for hypertension and coronary disease management.

Related Concept Videos

Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...